The Role of Secondary Surgery in Recurrent Ovarian Cancer

الملخص EN

Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease.

Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials.

A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.